Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis
- PMID: 30370423
- PMCID: PMC6201280
- DOI: 10.26717/BJSTR.2018.02.000738
Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis
Abstract
It is universally agreed that dopamine is a major neurotransmitter in terms of reward dependence, however, there remains controversy regarding how to modulate its role clinically to treat and prevent relapse for both substance and non-substance-related addictive behaviors. It is also agreed by most that there is a need to provide early genetic identification possibly through a novel researched technology referred to Genetic Addiction Risk Score(GARS).™ The existing FDA-approved medications promote blocking dopamine, however, we argue that a more prudent paradigm shift should be biphasic-short-term blockade and long-term upregulation, enhancing functional connectivity of brain reward. It is critical to understand that the real phenotype is not any specific drug or non -drug addictive behavior, but instead is Reward Deficiency Syndrome (RDS). Thus the true phenotype of all addictive behaviors is indeed RDS. Finally, we are suggesting that one way to combat the current out of control Opioid /Alcohol crisis worldwide is to seriously reconsider treating RDS by simply supplying powerful narcotic agents (e.g. Buprenorphine). This type of treatment will only keep people addicted. A more reasonable solution involving genetic testing, urine drug screens using Comprehensive Analysis of Reported Drugs (CARD) and dopamine homeostasis we call " Precision Addiction Management" ™ seems parsonomiuos.
Keywords: Genetic addiction risk score; Hypo dopaminergic; Pro-dopamine regulation; Reward deficiency syndrome.
Figures

Similar articles
-
Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).J Syst Integr Neurosci. 2020 Aug;6(2):10.15761/JSIN.1000221. doi: 10.15761/JSIN.1000221. Epub 2019 Dec 19. J Syst Integr Neurosci. 2020. PMID: 33614164 Free PMC article.
-
Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?Mol Neurobiol. 2015 Dec;52(3):1862-1869. doi: 10.1007/s12035-015-9110-9. Epub 2015 Mar 10. Mol Neurobiol. 2015. PMID: 25750061 Free PMC article. Review.
-
Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).Subst Use Misuse. 2017 Mar 21;52(4):535-547. doi: 10.1080/10826084.2016.1244551. Epub 2016 Dec 29. Subst Use Misuse. 2017. PMID: 28033474 Free PMC article.
-
Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS).J Neurol Sci. 2020 Apr 15;411:116733. doi: 10.1016/j.jns.2020.116733. Epub 2020 Feb 14. J Neurol Sci. 2020. PMID: 32088516 Review.
-
Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated).CPQ Neurol Psychol. 2018;1(2):https://www.cientperiodique.com/journal/fulltext/CPQNP/1/2/13. Epub 2018 Dec 4. CPQ Neurol Psychol. 2018. PMID: 30957097 Free PMC article.
Cited by
-
Summary Document Research on RDS Anti-addiction Modeling: Annotated Bibliography.J Addict Psychiatry. 2024 Apr 5;8(1):1-33. J Addict Psychiatry. 2024. PMID: 38765881 Free PMC article.
-
A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management".Psychol Res Behav Manag. 2021 Dec 17;14:2115-2134. doi: 10.2147/PRBM.S292958. eCollection 2021. Psychol Res Behav Manag. 2021. PMID: 34949945 Free PMC article. Review.
-
Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation.J Pers Med. 2022 Jun 20;12(6):1009. doi: 10.3390/jpm12061009. J Pers Med. 2022. PMID: 35743793 Free PMC article.
-
Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency.J Addict Sci. 2020 Jan 1;6(1):1-4. J Addict Sci. 2020. PMID: 32432229 Free PMC article. No abstract available.
-
Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).J Syst Integr Neurosci. 2020 Aug;6(2):10.15761/JSIN.1000221. doi: 10.15761/JSIN.1000221. Epub 2019 Dec 19. J Syst Integr Neurosci. 2020. PMID: 33614164 Free PMC article.
References
-
- Blum K, Kozlowski GP (1990) Ethanol and neuromodulator interactions: a cascade model of reward. Alcohol and behavior. In: Ollat H, Parvez S, Parvez H (Eds.). Alcohol and Behaviour: Basic and Clinical Aspects Progress in Alcohol Research VSP International Science Publishers. Utrecht, Netherlands, 131–149.
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous